<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316002</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 25514</org_study_id>
    <nct_id>NCT02316002</nct_id>
  </id_info>
  <brief_title>Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see how well the experimental drug pembrolizumab&#xD;
      (MK-3475) works in people with oligometastatic NSCLC who have already had treatment for their&#xD;
      disease. All patients will receive 200 mg of pembrolizumab intravenously on Day 1 of each&#xD;
      21-day cycle. Patients will receive the study drug for up to 8 cycles, and then if their&#xD;
      disease is doing well and the study doctor thinks they will benefit patients may receive&#xD;
      pembrolizumab for up to 8 more cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Time to progression or death from initiation of LAT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Oligometastatic Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 200 mg every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent for the trial.&#xD;
&#xD;
          -  18 years of age on day of signing informed consent.&#xD;
&#xD;
          -  Completion of definitive therapy 4-12 weeks prior to enrollment. There are no specific&#xD;
             limitations on which treatment modalities can be used in the definitive setting (e.g.&#xD;
             the use of adjuvant chemotherapy is acceptable), but all other treatments must be&#xD;
             complete at least 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Provision of tissue from an archival tissue sample or newly obtained core or&#xD;
             excisional biopsy of a tumor lesion.&#xD;
&#xD;
               1. Tumor tissue may be from a diagnostic biopsy or a portion of a surgical specimen,&#xD;
                  if surgery is a component of definitive intent therapy.&#xD;
&#xD;
               2. Formalin fixed paraffin embedded (FFPE) tissue samples are acceptable; a fine&#xD;
                  needle aspirate, frozen sample, plastic embedded sample, cell block, clot, bone,&#xD;
                  bone marrow or cytologic specimen will not be acceptable for IHC analysis.&#xD;
&#xD;
               3. It is recommended that FFPE blocks be sectioned fresh (within 7 days of&#xD;
                  sectioning and sending for PD-L1 analysis) onto positively charged slides; slides&#xD;
                  should be stored and shipped (and stored upon receipt at Qualtek) at 2-8C in the&#xD;
                  dark.&#xD;
&#xD;
               4. Recommended fixation time for samples is 24 hours to 48 hours in 10% neutral&#xD;
                  buffered formalin.&#xD;
&#xD;
          -  Performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Adequate organ function, all screening labs should be performed within 10 days of&#xD;
             treatment initiation.&#xD;
&#xD;
        Absolute neutrophil count&#xD;
&#xD;
          -  1,250 /mcL Product: Pembrolizumab Protocol/Amendment No.: 09/19/2014 10 (ANC)&#xD;
             Platelets&#xD;
&#xD;
          -  100,000 / mcL Hemoglobin&#xD;
&#xD;
          -  9 g/dL or ≥5.6 mmol/L Renal Serum creatinine OR Measured or calculateda creatinine&#xD;
             clearance (GFR can also be used in place of creatinine or CrCl)&#xD;
&#xD;
             ≤1.5 X upper limit of normal (ULN) OR&#xD;
&#xD;
          -  50 mL/min for subject with creatinine levels &gt; 1.5 X institutional ULN Hepatic Serum&#xD;
             total bilirubin&#xD;
&#xD;
               -  1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels &gt;&#xD;
                  1.5 ULN AST (SGOT) and ALT (SGPT)&#xD;
&#xD;
               -  2.5 X ULN OR&#xD;
&#xD;
               -  5 X ULN for subjects with liver metastases aCreatinine clearance should be&#xD;
                  calculated per institutional standard.&#xD;
&#xD;
                    -  Female subject of childbearing potential should have a negative urine or&#xD;
                       serum pregnancy within 72 hours prior to receiving the first dose of study&#xD;
                       medication. If the urine test is positive or cannot be confirmed as&#xD;
                       negative, a serum pregnancy test will be required.&#xD;
&#xD;
                    -  Female subjects of childbearing potential should be willing to use 2 methods&#xD;
                       of birth control or be surgically sterile, or abstain from heterosexual&#xD;
                       activity for the duration of the study through 120 days after the last dose&#xD;
                       of study medication. Subjects of childbearing potential are those who have&#xD;
                       not been surgically sterilized or have not been free from menses for &gt; 1&#xD;
                       year.&#xD;
&#xD;
                    -  Male subjects who are partnered with women of childbearing potential should&#xD;
                       be willing to use 2 methods of birth control, be surgically sterile or&#xD;
                       abstain from heterosexual activity for the duration of the study through 120&#xD;
                       days after the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently participating in or has participated in a study of an investigational agent&#xD;
             or using an investigational device within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or exposure to systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment (Nasal or oral inhalers are permissible).&#xD;
&#xD;
          -  Prior monoclonal antibody within 4 weeks prior to study Day 1 or individuals who have&#xD;
             not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2&#xD;
             weeks prior to Day 1 drug administration on study or inability to recover (i.e., ≤&#xD;
             Grade 1 or at baseline) from adverse events due to a previously administered agent.&#xD;
&#xD;
          -  Note: Subjects with ≤ Grade 2 neuropathy or alopecia are exceptions to this criterion&#xD;
             and may qualify for the study.&#xD;
&#xD;
          -  Note: If subject had major surgery, they must have recovered adequately from the&#xD;
             toxicity and/or complications from the intervention prior to starting therapy.&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, non-invasive bladder tumors, or in situ cervical cancer&#xD;
&#xD;
          -  Known untreated central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment within the past 3 months or a&#xD;
             documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy are an exception to this rule. Subjects that require&#xD;
             intermittent use of bronchodilators or local steroid injections are not excluded from&#xD;
             the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's&#xD;
             syndrome are not excluded from the study.&#xD;
&#xD;
          -  Evidence of pre-existing interstitial lung disease or active, non-infectious&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Active infection requiring systemic therapy with IV antibiotics&#xD;
&#xD;
          -  History or current evidence of any condition, therapy, or laboratory abnormality that&#xD;
             might confound the results of the trial, interfere with the subject's participation&#xD;
             for the full duration of the trial, or is not in the best interest of the subject to&#xD;
             participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Known psychiatric or substance abuse disorders that would interfere with cooperation&#xD;
             with the requirements of the trial.&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).&#xD;
&#xD;
          -  Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
          -  Known active Hepatitis B (e.g., HBsAg positive or HBV DNA detectable) or Hepatitis C&#xD;
             (e.g., HCV RNA [qualitative] is detected).&#xD;
&#xD;
          -  Receipt of live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Progressive disease or sites of new metastasis after definitive therapy for&#xD;
             oligometastatic disease.&#xD;
&#xD;
          -  Completion of definitive therapy for oligometastatic disease greater than 12 weeks&#xD;
             prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Bauml, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <results_first_submitted>October 14, 2019</results_first_submitted>
  <results_first_submitted_qc>November 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2019</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02316002/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab</title>
          <description>Pembrolizumab 200 mg every 3 weeks&#xD;
Pembrolizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab</title>
          <description>Pembrolizumab 200 mg every 3 weeks&#xD;
Pembrolizumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="46" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Time to progression or death from initiation of LAT</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Pembrolizumab 200 mg every 3 weeks&#xD;
Pembrolizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Time to progression or death from initiation of LAT</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="9.4" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>As per CTCAE</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab</title>
          <description>Pembrolizumab 200 mg every 3 weeks&#xD;
Pembrolizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joshua Bauml</name_or_title>
      <organization>University of Pennsylvania (Abramson Cancer Center)</organization>
      <phone>215-662-4000</phone>
      <email>melissa.volpe@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

